medicalcannabis
Several European cannabis start-ups are considering listing in New York as the Federal authorities propose to declassify marijuana as a less dangerous drug. This mainly involves companies who have still not made a concrete decision about when and where to list, but are being increasingly attracted by what they see as a more welcoming approach to marijuana and cannabidiol (CBD) products generally in the US. According to Statista, the value of the CBD products market could reach around $6.90 billion (€6.32 billion) this year. Under the new US rule, marijuana could be changed because of its medic...
Euronews (English)
The US Drug Enforcement Administration (DEA) has initiated proceedings to reclassify cannabis from a Schedule I substance to a Schedule III substance, marking a significant step towards cannabis reform in the country. After months of deliberation, the Associated Press reported on April 30 that the DEA would move to reclassify cannabis from Schedule I, a category it currently shares with heroin and methamphetamines, to Schedule III, which is reserved for substances with low potential for dependence and accepted medical use. The move from the DEA comes almost a year after the Department of Healt...
Investing News Network
The US government proposed a rule change to reclassify marijuana as a less dangerous drug. The historic move would recognise its use medically in the US and acknowledge it has less potential for abuse than other drugs. The US Attorney General submitted a proposal on Thursday to move it from a schedule I to a schedule III drug under the US Controlled Substances Act (CSA). German MPs approve new cannabis law allowing limited possession and cultivation of marijuanaSchedule I drugs are those "with no currently accepted medical use and a high potential for abuse" such as heroin and LSD, while sched...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら